Effect Of Withania Coagulans And Liraglutide On Serum Glp-1, Postprandial And Fasting Blood Glucose In Streptozotocin Induced Diabetic Rats

Authors

  • Abdul Samad
  • Noor Nasir Rajpoot
  • Hira Ayaz
  • Noman Sadiq

DOI:

https://doi.org/10.51985/JBUMDC2018125

Keywords:

Diabetes, GLP-1, Liraglutide, Withania coagulan

Abstract

Objective: To evaluate effect of Withania coagulans and liraglutide on serum Glucagon like peptide-1, Postprandial and
Fasting Blood Glucose levels in streptozotocin induced diabetic rat.
Study Design and Setting: This randomize control trile was conducted at Islamic International Medical College in
collaboration with National Institute of Health Islamabad.
Methodology: This randomized controlled study was performed on a total of forty male Sprague dawly rats, which were
initially divided into two groups; Group A (n=10) and Experimental Group (n=30). Diabetes in the Experimental group B
was induced by intraperitoneal administration of streptozotocin for 5 days (30mg/kg/day). Diabetes was checked in
experimental group by measuring fasting blood glucose (mg/dl) on day 6. Experimental group was further divided into
Group B (Diabetic control), Group C (Withania coagulans-treated) and Group D (Liraglutide-treated). Blood sampling was
done at day 30 and serum GLP-1, postprandial and fasting blood glucose levels were measured and compared in all groups.
Results: Fasting and postprandial blood glucose levels of group C and D were significantly reduced as compared to group
B. Serum GLP-1 levels were significantly increased in group C and D as compared to group B.
Conclusion: Withania coagulans reduces hyperglycemia in diabetic rats through increasing GLP-1 hormone.

References

Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and clinical practice. 2017; 128: 40-50.

American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018; 41:13-27.

Krinsley JS, Maurer P, Holewinski S, Hayes R, McComsey D, Umpierrez GE, Nasraway SA. Glucose control, diabetes status, and mortality in critically ill patients: the continuum from intensive care unit admission to hospital discharge. In Mayo Clinic Proceedings 2017; 92(7):1019-29.

Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T, Lauritzen T, Sandbæk A, Holst JJ. Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screen-detected type 2 diabetes and obesity, and influenced by sex: the ADDITION-PRO study. Diabetes. 2015: db141751.

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial. Diabetologia. 2009; 52(10): 2046-55.

Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41(2): 258-66.

Kumari P, Nakata M, Zhang BY, Otgon-Uul Z, Yada T. GLP-1 receptor agonist liraglutide exerts central action to induce â-cell proliferation through medulla to vagal pathway in mice. Biochemical and biophysical research communications. 2018; 499(3): 618-25.

Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. International journal of technology assessment in health care. 2012; 28(4): 436-44.

DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of internal medicine. 2000; 133(1):73-79.

Kumar Bharti S, Krishnan S, Kumar Sharma N, Kumar A, Prakash O, Kumar Gupta A, Kumar A. In vivo and in silico Investigation of Antidiabetic Activity of Fruit of Withania coagulans Dunal. Current hypertension reviews. 2015; 11(2): 143-58.

Hussain W, Badshah L, Ullah M, Ali M, Ali A, Hussain F. Quantitative study of medicinal plants used by the communities residing in Koh-e-Safaid Range, northern Pakistani-Afghan borders. Journal of ethnobiology and ethnomedicine. 2018; 14(1): 30-36.

Pande KH, Salve PS, Rai RK, Bali NR, Wankhede HS. Investigation and In vivo Demonstration of Synergistic Antidiabetic activity of Aqueous Extract of Aegle marmelos and Withania coagulans. Research journal of Pharmacology and Pharmacodynamics. 2014; 6(2): 101.

Siddiqui M, Akhtar M, Azmat J, Khalique A. A Comparative Clinical Study of Unani Formulation (Maghz Tukhm-e-Jamun wa Tukhm-e-Hayat) and Metformin in the Management of Ziabetus Shakari (Type 2 Diabetes Mellitus). Medical Journal of Islamic World Academy of Sciences. 2017; 25(2): 40-49.

Datta A, Bagchi C, Das S, Mitra A, De Pati A, Tripathi SK. Antidiabetic and antihyperlipidemic activity of hydroalcoholic extract of Withania coagulans Dunal dried fruit in experimental rat models. Journal of Ayurveda and integrative medicine. 2013; 4(2): 99-105.

Jaiswal D, Rai PK, Watal G. Antidiabetic effect of Withania coagulans in experimental rats. Indian Journal of Clinical Biochemistry. 2009; 24(1): 88-93.

Alam A, Siddiqui MY, Hakim MH. Clinical efficacy of Withania coagulans Dunal and Trigonella foenum-graecum Linn. in Type 2 Diabetes mellitus.

Bharti SK et al. Antidiabetic effect of aqueous extract of Withania coagulans flower in Poloxamer-407 induced type 2 diabetic rats. Journal of Medicinal Plants Research. 2012; 6(45): 5706-13.

S. Hemlatha et al. Chansouria; Hypolipidemic activity of aqueous extract of Withania coagulans Dunal in albino rats, Phytotherapy Research. 2006; 20(7): 614– 17.

Shukla K, Dikshit P, Shukla R, Gambhir JK. The aqueous extract of Withania coagulans fruit partially reverses nicotinamide/streptozotocin-induced diabetes mellitus in rats. Journal of medicinal food. 2012; 15(8): 718-25.

Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, Kaku K. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011; 54(5): 1098-108.

Lee A, et al.The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes, Obesity and Metabolism. 2002; 4(5): 329-35.

Downloads

Published

2019-06-05

How to Cite

Samad, A. ., Rajpoot, N. N. ., Ayaz, H. ., & Sadiq, N. . (2019). Effect Of Withania Coagulans And Liraglutide On Serum Glp-1, Postprandial And Fasting Blood Glucose In Streptozotocin Induced Diabetic Rats. Journal of Bahria University Medical and Dental College, 9(2), 120–123. https://doi.org/10.51985/JBUMDC2018125

Issue

Vol. 9 No. 2 (2019): Volume 9 Issue 2

Section

Original Articles

License

Copyright (c) 2019 Abdul Samad, Noor Nasir Rajpoot, Hira Ayaz, Noman Sadiq

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0